l e t t e r s
Protein ubiquitination is a post-translational modification (PTM) that regulates various aspects of protein function by different mechanisms. Characterization of ubiquitination has lagged behind that of smaller PTMs, such as phosphorylation, largely because of the difficulty of isolating and identifying peptides derived from the ubiquitinated portion of proteins. To address this issue, we generated a monoclonal antibody that enriches for peptides containing lysine residues modified by diglycine, an adduct left at sites of ubiquitination after trypsin digestion. We use mass spectrometry to identify 374 diglycine-modified lysines on 236 ubiquitinated proteins from HEK293 cells, including 80 proteins containing multiple sites of ubiquitination. Seventy-two percent of these proteins and 92% of the ubiquitination sites do not appear to have been reported previously. Ubiquitin remnant profiling of the multi-ubiquitinated proteins proliferating cell nuclear antigen (PCNA) and tubulin -1A reveals differential regulation of ubiquitination at specific sites by microtubule inhibitors, demonstrating the effectiveness of our method to characterize the dynamics of lysine ubiquitination.
Protein ubiquitination occurs on a wide variety of eukaryotic proteins and affects processes ranging from protein degradation and subcellular localization to gene expression and DNA repair 1 . Ubiquitination involves the transfer of ubiquitin to a target protein using E1 ubiquitinactivating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubi quitin ligases 1 . This process typically leads to the formation of an amide linkage comprising the εamine of lysine of the target protein and the C terminus of ubiquitin, and can involve ubiquitination at distinct sites within the same protein, although the roles of ubiquitination at distinct sites are incompletely understood. The human genome is predicted to encode 16 E1, 53 E2 and 527 E3 proteins 2 , which underscores the likely importance of ubiquitination in molecular signaling.
In most cases, proteins suspected to be ubiquitinated have been identified based on their susceptibility to proteasomemediated deg radation, as evidenced by their increased levels following application of proteasome inhibitors. These proteins are immunopurified and ubiquitin adducts are confirmed by antiubiquitin immunoblotting 3 . Mutagenesis experiments can identify ubiquitination sites 4 . Global identification of ubiquitinated proteins has been performed by purifying ubiquitinated proteins, using ubiquitinbinding proteins such as antiubiquitin antibodies 5 , or by purifying hexahistidine (His 6 )tagged ubiquitinprotein conjugates 6 . The enriched set of pro teins are then proteolyzed and subjected to tandem mass spectrometry (MS/MS). However, as only one or a few lysines are typically modified in any ubiquitinated protein, most peptides do not exhibit any ubiquitinderived modifications 7 . This introduces uncertainty whether they are derived from the nonubiquitinated portion of a protein or from coprecipitated proteins.
Alternatively, proteolytic digests can be screened for peptides that contain remnants of ubiquitin modification. Digestion of ubiquitin conjugated proteins results in peptides that contain a ubiquitin rem nant derived from the ubiquitin C terminus. The three Cterminal residues of ubiquitin are ArgGlyGly, with the Cterminal glycine conjugated to a lysine residue in the target. After digestion with trypsin, ubiquitin is cleaved after arginine, leaving a GlyGly dipep tide remnant on the conjugated lysine. Therefore, tryptic digests will include peptides that contain a diglycinemodified lysine, indicating the prior conjugation of ubiquitin to that region of the target protein. The diglycinemodified lysine serves as a signature of ubiquitination and also identifies the specific site of modification. Sequencing of ubiquitin remnant-containing peptides in tryptic digests has been used to identify 110 ubiquitination sites from yeast expressing His 6 ubiquitin 7 . Despite the availability of these approaches for several years, analysis of the SwissProt database indicates that only 255 mammalian proteins have been reported to be ubiquitinated based on experimental evidence. In most cases, the ubiquitination sites have not been identified. Direct enrichment of ubiquitin remnant-containing peptides would facilitate the high throughput identification of ubiquitination sites.
To identify ubiquitinated proteins and simultaneously report their sites of ubiquitination, we generated an antibody that recognizes peptides containing the ubiquitin remnant left after trypsin digestion of ubiquitinated proteins. To prepare a protein antigen containing diglycinemodified lysines, we first reacted purified lysinerich histone IIIS protein with tbutyloxycarbonylGlyGlyNhydroxysuccinimide (BocGlyGlyNHS) to introduce amidelinked BocGlyGly adducts on all amines (Fig. 1a) . Nearly complete modification of the amines was confirmed by the reduction in labeling of the BocGlyGly-modified protein by the lysinemodifying reagent biotinNHS, as assessed by antibiotin immunoblotting (Fig. 1b) . The modified protein was treated with trifluoroacetic acid (TFA) to remove the Boc moiety. Quantitative l e t t e r s conversion of the BocGlyGly adduct, which does not contain an amine, to GlyGly, which contains an amine, was confirmed by the reactivity of the TFAtreated protein with biotinNHS (Fig. 1b) .
We injected the diglycinemodified histone into mice, and screened hybridoma lines for antibodies that specifically recognize proteins containing diglycinemodified lysines. Hybridoma line GX41 gener ated monoclonal antibodies that exhibited pronounced specificity for proteins containing the diglycinemodified lysines. The antibodies failed to interact with unmodified lysozyme or lactoglobulin (Fig. 1c) , or either of these proteins after they have been modified with BocGly Gly. However, the antibody recognized GlyGly-modified lysozyme and lactoglobulin obtained after removal of the Boc group.
These results indicate that the antibody recognizes GlyGly-modified lysines, and suggest that the antibody only recognizes GlyGly adducts that contain an unmodified primary amine. Similarly, the antibody exhibits negligible reactivity with rat brain lysate (Fig. 1c) , or brain lysate modified with BocGlyGly, but exhibits substantial reactivity with GlyGly-modified proteins from brain lysate. Notably, the brain lysate includes highly abundant proteins containing internal Gly Gly peptide sequences, such as βactin, glyceraldehyde3phosphate dehydrogenase and αtubulin, as well as histone H2A, which contains an internal GlyGlyLys sequence. This indicates that internal GlyGly sequences are not recognized by the antibody. Additionally, peptides that contain GlyGly as the first two amino acids are not recognized (Supplementary Fig. 1 ). Together, these data indicate that the anti body recognizes GlyGly sequences that are present as an adduct on the εamine of lysine.
We next investigated whether the anti-diglycyllysine antibody was able to immunoprecipitate peptides containing GlyGly-modified lysine. A flow chart for sample preparation, immunoprecipitation, and MS/MS analysis is shown in Figure 2a . We prepared a peptide containing an Nterminal GlyGly sequence (GGDRVYIHPFHL), and a peptide con taining a diglycyl adduct on lysine (AcSYSMEHFRWGK*PVNH 2 ; K* and Ac represent GlyGly-modified lysine and an acetyl group, respec tively). An equimolar mixture of the peptides was immunoprecipitated with the anti-diglycyllysine antibody, resulting in selective enrichment (≥50×) of the peptide containing the GlyGly-modified lysine (Fig. 2b) . Additionally, this peptide was quantitatively immunoprecipitated with a nearly 100% yield (Supplementary Fig. 2) . These experiments demonstrated that the GX41 antibody is capable of enriching peptides containing diglycinemodified lysines and does not immunoprecipitate peptides containing a GlyGly sequence at their N termini.
We next sought to assess the diversity of lysine ubiquitination in cultured cells. To distinguish diglycine remnants derived from ubiqui tin from those originating from less common ubiquitinlike proteins (such as ISG15 and NEDD8, which also leave a diglycine remnant on lysines after trypsinization 8 ), we used HEK293 cells express ing His 6 tagged ubiquitin. Ubiquitinated proteins were purified by immobilized metalaffinity chromatography, before proteolysis and anti-diglycyllysine immunopurification. Ubiquitin remnantcontaining peptides were subjected to liquid chromatography (LC) MS/MS followed by database searching and spectral validation. To minimize alterations in ubiquitination levels after cell lysis, 5 mM chloroacetamide was included in lysis buffer to inhibit deubiquitinase and ubiquitin ligase activity 9 . To measure postlysis ubiquitination, we spiked a lysate with excess glutathione Stransferase. This protein showed no detectable level of ubiquitination (Supplementary Fig. 3 ), suggesting that negligible ubiquitination occurred after cell lysis.
MS/MS spectra of ubiquitin remnant-containing peptides exhibited normal y and bion series, typically with a pair of ions separated by a mass of 242.14 Da, consistent with the masses of a lysine residue (128.09) and a GlyGly adduct (114.04 Da) on the εamine of lysine. Whereas most peptides contained a single diglycinemodified lysine (Fig. 2c) , 17 peptides contained two diglycinemodified lysines. The majority (>92%) of ubiquitin remnant-containing peptides have a +3 or +4 charge ( Supplementary Fig. 4) , which reflects the additional charge from the Nterminal amine on the GlyGly adduct. GlyGly-modified lysines as the Cterminal residue of peptides were also detected (~2% of total) (Supplementary Fig. 5 ), and reflect use of the GlyGly-modified lysine as a substrate for trypsin, as described previously 10 .
In total, we identified 374 diglycinemodified lysines on 236 ubi quitinated mammalian proteins. Analysis of the SwissProt database suggests that 72% of these proteins were not previously known to be ubiquitinated. Similarly, 92% of the ubiquitination sites that we identified were not previously known. Among the identified proteins, 156 proteins have one ubiquitination site and 80 have two or more ubiquitination sites (Supplementary Table 1 and Supplementary  Fig. 6 ). To validate the ubiquitination detected using the ubiquitin Figure 1 Generation of monoclonal antibodies that selectively recognize diglycine-modified lysines. (a) The antigen used to raise antibodies was synthesized by modifying the ε-amines of all lysines in a histone with t-butyloxycarbonyl-Gly-Gly-N-hydroxysuccinimide (Boc-Gly-Gly-NHS) and then removing the Boc group by treatment with TFA. The lysines in the final protein contain Gly-Gly adducts on the ε-amine of all lysine residues. (b) To validate the synthesis of Gly-Gly-modified histone, we monitored the reaction of the histone with Boc-Gly-Gly-NHS by detecting amines, such as those in unmodified lysine, through the reaction of the protein with the amine-modifying agent biotin-NHS, and subsequent western blot analysis with an anti-biotin antibody. Amines in the histone were completely lost after treatment with Boc-Gly-Gly-NHS, indicating complete modification of all the lysines in the histone. Removal of the Boc protecting group with TFA resulted in the formation of an amine at the N terminus of the Gly-Gly adduct. This step was essentially complete, as the TFA-treated protein exhibited nearly complete recovery of amine reactivity. The position of the bands in the different samples is slightly shifted due to the different molecular weights and number of positive charges in the modified and unmodified samples. The bands above 50 kDa represent impurities in the histone sample. (c) We evaluated the specificity of the GX41 monoclonal antibody by western blot analysis of β-lactoglobulin, lysozyme or rat brain lysate, in which the lysines were either unmodified (A), or modified with Boc-Gly-Gly (B) or Gly-Gly-(C) adducts, respectively. l e t t e r s remnant-profiling approach, we selected a subset of six proteins iden tified by MS and assessed whether they were ubiquitinated in cells.
Lysates from HEK293 cells were immunoprecipitated with antibodies specific for the protein under investigation and immunoblotted using an antiubiquitin antibody (Fig. 2d) . In these experiments, the HEK293 cells were not transfected with plasmids expressing His 6 tagged ubiquitin. In each case, the immunopurified protein exhibits antiubiquitin immunoreactivity consistent with the endogenous ubiquitination of these proteins.
The ubiquitination targets include diseaserelated proteins, such as 1433ε, ataxin, βcatenin, BRCA1associated protein and TTRAP (TRAF and TNF receptorassociated protein). The proteins identi fied by ubiquitin remnant profiling have roles in numerous biological processes, of which the largest number involve metabolism, cell cycle/ apoptosis and signal transduction (Fig. 3a) . Additionally, we identified proteins that influence the trafficking, localization and structure of proteins, as well as regulate the immune system, consistent with previ ously reported roles for ubiquitination [11] [12] [13] [14] . Ubiquitination of many ubiquitinconjugating enzymes, ubiquitin ligases and 26S proteasome regulatory subunits also supports previous studies that reported the prevalence of ubiquitination of proteins involved in proteasome degradation pathways 15, 16 . Some of the proteins found to be ubiqui tinated extend earlier findings regarding the role of ubiquitination in certain cellular processes. For example, although histone H2 ubiquitina tion has been described 3 , we found that histone H1, H3 and H4 isoforms are also ubiquitinated, as are subunits of histone acetyltransferases and histone deacetylases. These findings support the idea that ubiquitin contributes to epigenetic gene regulation through multiple path ways. Many heat shock proteins, such as HSP70, HSP105, and HSC71, are ubiquitinated, linking ubiquitination to stress responses. Ubiquitination of several heterogeneous nuclear ribonucleoproteins reveals a role for ubiquitination in mRNA processing, metabolism, transport and splicing. Our studies also identify numerous transcrip tion factors, splicing factors, DNA repair proteins and kinases. This supports the wellcharacterized role for ubiquitination in regulating cellular signal transduction.
The subcellular distribution of the detected proteins is likely to reflect, in part, the subcellular fractions that were used for MS/MS analysis. Subcellular localization analysis of the identified proteins indicates that essentially all the ubiquitinated proteins are cytosolic (Fig. 3a, right panel) , which is consistent with the general observation that ubiquitination occurs primary in the cytosolic compartment of the cell 12 . Many of the identified proteins are localized to the nucleus, and several proteins are localized to the mitochondria, suggesting a role for ubiquitination in regulating aspects of mitochondrial function.
We next wanted to gain insight into how lysine ubiquitination might be regulated at the level of primary and secondary structure. Interestingly, ubiquitin remnant-modified lysines have a slight tendency to be localized in regions enriched in small hydrophobic residues, such as alanine, leucine, isoleucine, glycine, proline and valine ( Supplementary Fig. 7a ). Examination of a sixaminoacid window adjacent to ubiquitinated lysines in the human proteome revealed that cysteine, histidine and lysine are found at a ~40% lower frequency than when they are adjacent to lysines in general Proteins were immunoprecipitated using target-specific antibodies and the immunoprecipitate was detected by western blotting using an anti-ubiquitin antibody. IgG was used as a control for nonspecific immunoprecipitation.
The proteasome inhibitor N-acetyl-LeuLeu-norleucinal (LLnL) was added to allow accumulation of the ubiquitinated protein.
l e t t e r s (Supplementary Fig. 7a ). Analysis involving Motifx 17 identified K*XL as a potential consensus ubiquitination site. This motif appears to be ~1.8 times more common among ubiquitinated lysines than lysines in general (Supplementary Fig. 7b ). To compare all 20 amino acids for their propensity to be found at specific residues adjacent to ubiquitinated lysines, we prepared a density map that indicates the frequency of each amino acid at any of the ten proximal positions on either side of the ubiquitinated lysines, compared to the frequency of that amino acid next to lysines in general, as assessed by surveying the human proteome (Fig. 3b) . This analysis shows that there is only a subtle enrichment for specific residues at some positions, such as leucine at the +2 position, valine at the −2 position, alanine at the −5 position, glycine at the +6 position, and tyrosine at the −1 and +1 positions. In contrast, an analysis of ubiquitinated proteins in yeast 7 indicates an significant enrichment of aspartic acid, glutamic acid, histidine and proline at some positions (Supplementary Fig. 7c ).
To determine whether the sequence of the immunogen affected the specificity of the immunoprecipitated peptides, we generated a similar density map to present the frequency of each amino acid adjacent to the GlyGly-modified lysines in the immunogen. Although there are marked amino acid preferences adjacent to lysine in the immunogen (Supplementary Fig. 7d ), these preferences are not seen in peptides pulled down by the anti-diglycyllysine antibody ( Supplementary  Fig. 7d ). This suggests that the sequence of the immunogen used to generate our immunoaffinity reagent does not substantially bias the sequences of the immunoprecipitated peptides the antibody recovers. We found that ubiquitinated lysines have a slight tendency to appear on protein surfaces in preferred structural contexts. Structural infor mation is available in Protein Data Bank (PDB) for 89 of the proteins identified in this study. Measurements of the solventaccessible area of lysines in these proteins indicate that ubiquitinated lysines tend to be exposed slightly more to solvent than other lysines (Fig. 3c , Student's t test, P < 0.001). If lysines with >50% surface exposure are considered solvent exposed 18 , 60% of the ubiquitinated lysines are exposed, which is more than for lysines in general (45%). Overall, ubiquitinated lysines are ~6.5% more exposed than all the lysines. This is in agreement with a ubiquitination site survey for yeast 19 . Interestingly, in some cases, the ubiquitinated lysine is fully buried (e.g., Supplementary Fig. 8 ). In these proteins, ubiquitination may be regulated by stimuli that induce the exposure of the lysine to the Figure 4 Colchicine differentially regulates the ubiquitination of two lysines in PCNA. HEK293 cells were grown in SILAC medium containing either light (Lys0) or heavy (Lys8) lysine, and transfected with a plasmid expressing His 6 -ubiquitin. Whereas Lys0-labeled cells were treated with 10 μM colchicine, Lys8-labeled cells were treated with vehicle for 16 h. Identical amounts of cells from each treatment were mixed and processed for MS analysis of ubiquitin remnant-containing peptides. The relative ratio of MS signals between Lys0-and Lys8-labeled peptides was used for relative quantification of the change in ubiquitination at K164 and K254. The observed ratio was normalized to the change in PCNA protein abundance in the two samples by measuring two unmodified PCNA peptides in the initial mixed cell lysate ( Supplementary Fig. 11 ). The observation that the ion intensity of the novel ubiquitination site (K254) is about 20% of that of K164 suggests that its ubiquitination may be less common or more transient than K164. This may explain why it was not detected previously in mutagenesis studies 33 . All data are the averages of experiments repeated three times. Note that the peptide ubiquitinated at K254 is the C-terminal tryptic peptide of the protein so that the last amino acid is neither K nor R, and the charge state of this peptide is +2. l e t t e r s surface. Analysis of the local secondary structure surrounding all lysines and ubiquitinated lysines indicates that ubiquitinated lysines prefer helical structures compared to all lysines, although ubiquiti nation sites can also be found in other structural contexts (Fig. 3d) . Additional crystal structures of proteins that are susceptible to ubiqui tination are needed to fully assess the solvent exposure and structural contexts of ubiquitinated lysines. Recently, a large number of lysine acetylation sites have been dis covered by proteomic approaches [20] [21] [22] [23] . Although only 0.6% of lysines are predicted to be acetylated based on yeast studies 24 , >20% of the lysines that we found to be ubiquitinated are also sites of acetylation. For example, all the ubiquitinated lysines in H2B, H3.1 and H4 were reported to be acetylated. In the case of tubulin α1A, four of the six ubiquitinated lysines were reported to be acetylated. The surprisingly high degree of concordance of lysine ubiquitination and acetylation sites suggests that acetylation of a specific lysine residue could serve as a means to prevent lysine ubiquitination 25 , or vice versa. A BLAST analysis of ubiquitination sites in human proteins against mouse, rat and yeast revealed that modified lysines are statistically more con served between these species than lysines in general ( Supplementary  Fig. 9 ). This suggests that the pathways leading to the ubiquitination of these sites may be evolutionarily conserved.
In cases where a protein is ubiquitinated at more than one site, it is particularly challenging to monitor how the ubiquitination at the indi vidual sites is independently regulated. We therefore examined two proteins exhibiting multiubiquitination: tubulin α1A and PCNA, a protein that regulates cell cycle progression 26 and has been linked to tumorigenesis 27 . We labeled His 6 ubiquitinexpressing HEK293T cells with either light (Lys0) or heavy (Lys8) lysine to quantify ubi quitination using the SILAC (stable isotope labeling by amino acids in cell culture) approach 28 (Supplementary Fig. 10 ). We treated cells for 16 h with either vehicle (Lys8) or 10 μM colchicine (Lys0), an inhibitor of microtubule polymerization that affects progression through the cell cycle 29 , before mixing, lysing and processing cells as described in the Online Methods. We then analyzed the samples by nanoLCMS to quantify ubiquitination at the PCNA ubiquitination sites that we had previously identified using MS/MS based on their retention time, masstocharge ratio (m/z) and charge states. We quantified relative ubiquitination at each modification site by normalization using pro tein abundance, as measured by the averaged lighttoheavy ratio of unmodified peptides detected from initial mixed cell lysate before any affinity purification 30 (Supplementary Fig. 11 ). Interestingly, whereas the ubiquitination of K164 was unaffected by colchicine treatment, the ubiquitination of K254 was increased by 47% (Fig. 4) .
We also examined the multiubiquitination of tubulin α1A. Treatment with colchicine resulted in a similar ~80% decrease in the ubiquitination of K326, K336 and K370. Surprisingly, treatment with vinblastine, which also disrupts microtubules, albeit through a distinct mechanism 31, 32 , resulted in an opposite effect on ubiquiti nation, with a ~40% increase in ubiquitination at each of these sites (Supplementary Figs. 12 and 13) . These results highlight how some ubiquitination sites may be ubiquitinated in a dynamic manner, for example, in response to specific signals, whereas other ubiquitination sites may be 'constitutive' . In the case of both PCNA and tubulin α1A, ubiquitin remnant profiling provided insights into how distinct ubiquitination sites respond to different experimental treatments in a manner not readily available using currently available approaches.
The ubiquitin remnant-profiling approach described here provides a simple and robust strategy to identify and quantify sites of ubi quitination in cells. It could be used to identify ubiquitination pat terns in cells and tissues with altered expression of ubiquitin ligases, deubiquitinating enzymes, as well as to profile changes in ubiquitina tion elicited by various signaling molecules, drugs and disease states. Although the present data used cells expressing His 6 tagged ubiquitin to reduce the likelihood of obtaining diglycinemodified peptides from ISG15 and NEDD8modified proteins, ubiquitinmodified proteins could readily be enriched using immobilized ubiquitinbinding proteins, such as S5a, or ubiquitin antibodies 5 
oNLINE METHodS
Antigen synthesis and antibody production. Lysinerich histone from calf thymus (type IIIS, Sigma) was dissolved in 100 mM NaHCO 3 buffer (10 ml) at pH 10. 500 μl tbutyloxycarbonylGlyGlyNhydroxysuccinimide (50 mM, BocGlyGlyNHS, ref. 34) in DMSO was added to histone solution and the reaction was carried out at 25° C for 1 h by constant shaking on a plate rotator. This step was repeated three additional times and sample B was obtained. For deprotection of the Boc group, neat trifluoroacetic acid (6 ml, TFA, Sigma) was added and the solution was shaken for 2 h at 25° C. The reaction was stopped by neutralizing with 10 M NaOH dropwise on ice (sample C). Sample A, B and C were dialyzed four times against 20 mM acetic acid followed by lyophilization. The degree of the reaction was assessed by antibiotin (Sigma) western blot analysis after samples A, B and C were reacted with 5 mM biotinNHS (Sigma) for 10 min. The same protocol was used to prepare BocGlyGly-and GlyGly-modified βlactoglobulin, hen egg white lysozyme, rat brain lysate and peptides (DRVYIHPFHL and AcSYSMEHFRWGKPVNH 2 ) for antibody evaluation.
The antigen was injected into mice for antibody production, and hybri doma clones were made by Promab. Cells of monoclonal clones were grown in MegaCell Dulbecco's Modified Eagle's Medium (MegaCell DMEM, pH 7.2, Sigma) supplemented with 10% FBS (FBS), 50 μg/ml of kanamycin, 1 mM glutamine, and cells were split and cell culture supernatant was collected every week.
Hybridoma clone GX41 was obtained after screening a panel of hybrido mas to assess their utility in detecting diglycinemodified lysines. Antibodies from each hybridoma clone were first evaluated by western blot analysis using GlyGly-modified βlactoglobulin, lysozyme and rat brain lysate. Clones were selected based on the absence of reactivity with unmodified protein and lysates, absence of reactivity with proteins and lysate modified with BocGlyGly, and reactivity with GlyGly-modified proteins and lysate. The top five clones that were further characterized were based on their ability to recognize the largest number of bands in the GlyGly-modified rat brain lysate. Antibodies from these clones were purified and used for immunoprecipitation of ubiquitin remnant-containing peptides from His 6 ubiquitin-expressing HEK 293 cells, and tandem MS identification of tryptic ubiquitinated peptides to assess the degeneracy of antibodies. Only clone GX41 pulled down peptides that con tained each of the 20 amino acids Nterminal to the modified lysine and each of the 20 amino acids Cterminal to the modified lysine, suggesting that the antibody can bind peptides which contain the diglycyllysine in a wide range of sequence contexts, which was supported by subsequent characterization of the amino acid context of the diglycyllysine obtained from a larger data set of ubiquitin remnant peptides ( Fig. 3b and Supplementary Fig. 7a ). The GX41 anti-diglycyllysine monoclonal antibody was found to be IgG1κ isotype. This antibody was used for all the experiments in this study.
Antibody purification and coupling. GlyGly-modified βlactoglobulin was coupled to AffiGel 10 resin (BioRad) in a concentration of 5 mg protein/ml resin in a pH 8 HEPES buffer overnight in 4 °C. The resin was quenched by 1 M TrisHCl (pH 8), washed with three volumes of 10 mM citric acid (pH 3) and PBS. Cell culture supernatant (50 ml) from monoclonal cell lines was loaded six times into an 8cm column with 1 ml AffiGel 10 resin coupled with GlyGly-modified βlactoglobulin in 4 °C using a peristaltic pump. The resin was washed three times with 6 ml of 2× PBS and three times with 6 ml of PBS. The antibody was eluted four times with 0.5 ml 10 mM citric acid (pH 3) and immediately neutralized by 50 μl of 1 M HEPES (pH 8). The pH was adjusted to 8.5 and the antibody was concentrated by a 15 ml filter device (30 kDa molecular weight cutoff, Millipore). The antibody concentration was measured by Bradford protein assay (BioRad). Typically, 0.1~0.2 mg of antibody was coupled to 20 μl AffiGel 10 resin according to the method described above. The antibody resin was stored in PBS buffer with 0.1% sodium azide at 4 °C.
Cell culture and sample preparation. Human embryo kidney (HEK) 293 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen) supplemented with 4.5 g/l glucose, 10% FBS, 100 units/ml penicillin G and 100 μg/ml streptomycin. When the confluence reached ~50%, cells were transfected with 10 μg of a His 6 tagged ubiquitin plasmid per 10cm Petri dish using the calcium phosphate transfection method. Cells were used 1 d after transfection and treated with vehicle or proteasome inhibitor 25 μM LLnL (Calbiochem) in DMSO and incubated for 16 h before harvest. The His 6 ubiquitin is expressed at a fraction of the level of endogenous ubiquitin (Supplementary Fig. 14) suggesting that it is unlikely to perturb endogenous ubiquitin pathways. The expression of tagged ubiquitin has been widely used in proteomics studies of protein ubiquitination 7, 35, 36 .
Twenty 10cm Petri dishes were cultured and cells were washed twice with icecold PBS. The cells were detached, collected and centrifuged at 1,000g for 5 min at 4 °C. To increase coverage of ubiquitinated proteins, crude lysates, as well as subcellular fractions, including nuclear, membrane and cytosolic frac tions, were prepared for analysis. For the crude lysate, the cell pellet was lysed and His 6 tagged proteins were purified by NiNTA resin (Qiagen) in native and denaturing conditions according to the manufacturer's protocol. The lysis buffer contained 5 mM chloroacetamide to alkylate cysteines and to inhibit ubiquitin ligases and deubiquitinases 9 . The membrane fraction was obtained by centrifuging at 100,000g for 60 min after removing the nuclear pellet in the presence of 250 mM sucrose. The pellet from nuclear and membrane fraction was dissolved in 8 M urea with 1% triton X100 and 0.1% SDS and the proteins were purified by NiNTA resin in the presence of 10 mM βmercaptoethanol. After immobilized metal affinity purification, ubiquitinated proteins are sig nificantly enriched (Supplementary Fig. 15 ).
All the samples after NiNTA purification were concentrated on an Amicon YM10 filter device (Millipore) and separated by SDSPAGE. Gel pieces were treated with 10 mM dithiothreitol at 50 °C for 30 min, followed by 55 mM chloroacetamide at 25 °C for 45 min, using methods described previously 37 , except that chloroacetamide was used in place of iodoacetamide. Ingel diges tion and peptide extraction were performed as described 37 .
The lyophilized peptide mixture was dissolved in 300 μl of buffer contain ing 150 mM NaCl, 50 mM TrisHCl (pH7.4) and 2 mM EDTA. The sample was boiled in a water bath for 10 min to deactivate residual trypsin activity. The peptide mixture was incubated with 20 μl antibody resin for 4 h in 4 °C, loaded on a microspin column (Pierce) six times, washed three times with 2× PBS and three times with PBS, and eluted six times with 20 μl 10 mM citric acid (pH 3). The eluted peptide mixture was concentrated to 20 μl for tandem MS analysis.
For the MALDITOFMS experiment, a sample containing ~0.3 nmol of each peptide, GGDRVYIHPFHL and AcSYSMEHFRWGK*PVNH 2 , was pre pared and subjected to immunoprecipitation using the agaroseimmobilized antibody described above.
For SILAC quantification, five 10cm dishes of HEK293T cells were grown in the media containing either light lysine (Lys0: 12 C 6 14 N 2 Lys) or heavy lysine (Lys8: 13 C 6 15 N 2 Lys) (Cambridge Isotope Labs) using previously described procedures for SILAC experiments 38 . The cells were transfected with His 6 ubiquitin plasmid as described above, and treated with vehicle or drugs (10 μM colchicine or 1 μM vinblastine, Sigma) in the presence of LLnL (PCNA: 25 μM for 16 h; tubulin α1A: 50 μM for 30 min). The cells were mixed and purified under denaturing condition as described above without fractiona tion. To normalize the ubiquitinated peptides by unmodified peptides in the cell lysate, a small amount of initial mixed cell lysate was digested by trypsin followed by tandem MS analysis 30 .
Mass spectrometric analysis. For MALDITOFMS, samples were desalted by Millipore C18 ZipTip according to manufacturer's protocol and eluted in a 2 μl solvent with 50% acetonitrile and 0.1% TFA in the presence of 10 mg/ml αcyano4hydroxycinnamic acid (Sigma). The masses of the samples were analyzed in the reflector mode by VoyagerDE PRO MALDITOFMS (Applied Biosystems).
The samples purified from cell lysate were analyzed by nanoLC QTOF MS/MS (Agilent) to obtain peptide sequence information using settings as described previously 39 . Briefly, 8 μl of peptide mixtures were loaded onto an enrichment column with 97% solvent A and 3% solvent B with a flow rate of 3 μl/min. Solvent A consists of 0.1% formic acid (Fluka) and solvent B of 90% acetonitrile (Fisher) and 0.1% formic acid. Peptides were eluted with a gradient from 3% to 40% solvent B in 20 min, followed by a steep gradient to 90% solvent B in 5 min at a flow rate of 0.3 μl/min. Mass spectra were acquired in the positiveion mode with automated datadependent MS/MS on the five most intense ions from precursor MS scans and every selected precursor peak was analyzed twice within 3 min. In some runs, a list of previ ous identified peptides was excluded for MS/MS fragmentation.
Database search of MS/MS spectra for peptide and protein identification.
Analysis of MS/MS spectra for peptide and protein identification was performed by protein database searching with Spectrum Mill software (Rev A.03.02, Agilent) against the SwissProt database (v57.2, May 5, 2009) containing a concatenated reverse database with the same entries and the same length for each protein, as described 40 . The use of a decoy database to evaluate the falsepositive rate for modified peptides may underestimate the false identifications as protein modifications can greatly expand the search space. Raw spectra were first extracted to MS/MS spectra that could be assigned to at least four y-or bseries ions. Scans with the same precursor within a mass window of ±0.4 m/z were merged within a time frame of ±15 s, charges up to a maximum of 7 were assigned to the precursor ion and the 12 C peak was determined by the Data Extractor. Key search parameters were a minimum matched peak intensity of 50%, a precursor mass tolerance of ±20 p.p.m., and a product mass tolerance of ±40 p.p.m. A fixed modifica tion was carbamidomethylation (same modification as chloroacetamide) for cysteines and variable modifications were GlyGly modification for lysines and oxidation for methionines. It should be noted that there are potentially a large number of naturally occurring sequence variants in mammals, but very limited data in the databases on these sequences. These variants may be missed or misidentified if the sequence variation lies in the same pep tide that contains the diglycine modified-lysine. The maximal number of diglycine modifications was set as two. Trypsin was selected as enzyme for sample digestion and four missed cleavages were allowed during the database search. The threshold used for peptide identification was a Spectrum Mill score of ≥ 9, an SPI% (the percentage of the scored peak intensity) of ≥ 50% and the difference between forward and reverse scores of ≥2. Under these criteria, the falsepositive rate is <1%. In the peptide list (Supplementary Table 1 ), only the highest scoring member of each peptide group is shown and only peptides with a charge state of 2, 3, 4 and 5 are reported. Finally, all MS/MS spectra were manually validated and the spectra with low quality of fragmentations were discarded.
For SILAC experiments that quantified the relative ubiquitination at spe cific sites in tubulin α1A and PCNA, quantification was performed using peak intensities from the MS data on peptides that were previously identified by MS/MS (included within Supplementary Fig. 6 and the manually anno tated MS/MS spectra are shown in Supplementary Fig. 16 ). Peptides were identified based on LCretention time, m/z and charge state as described 41, 42 . Quantification of relative ubiquitination at each modification site was obtained by normalization to protein abundance, as measured by the averaged light toheavy ratio of unmodified peptides detected from initial mixed cell lysate before any affinity purification as described previously 30 .
The two modifications isobaric to the GlyGly seen on the Delta Mass PTM website using a 0.02 Da mass window margin of error, which is appropriate for the QTOF instrument used in this study, are asparagyl and hydroxy prolylmodifications. The ornithyl modification is 0.04 Da larger than the diglycine modification. These rare modifications could be mistaken for the diglycine remnant on lysine. Alternatively, if these residues are adjacent to a lysine, the MS/MS ion series could be misinterpreted to contain a Gly Gly-modified lysine. However, none of the diglycinemodified lysine resi dues reported in this study were found in a peptide context that could have matched an alternate tryptic peptide with a lysine adjacent to an asparagine or hydroxyproline.
This paper describes the identification of several hundred diglycine modified peptides. Because of the large number of diglycinemodified peptides identified by Spectrum Mill, manual verification of every spectra proved to be impractical. Other than the spectra obtained for the tubulin α1A and PCNA experiments (Supplementary Fig. 16 ), we have not manually verified all the diglycinemodified lysine residues listed in Supplementary Table 1. To provide an alternate estimate of the accuracy of diglycyllysine modification identification in peptides, we used a combination of decoy database searching (described above), as well as the use of a consensus searching approach to report peptides that were identified by Spectrum Mill and at least one other search program. To identify Spectrum Millidentified peptides that were also matched by other search algorithms, the pkl files for ubiquitinated peptides identified by Spectrum Mill were extracted, converted and merged to a single file in Mascot Generic Format (mgf). The file was searched with other online search programs: Mascot, X!Tandem and Phenyx, against the SwissProt human database. The Mascot score and expectation value, X!Tandem log (e), and Phenyx pvalue are reported in Supplementary Table 1 Figure 17 . To increase the con fidence of our identification, only the peptides which were found by at least two search programs were considered as likely ubiquitinated peptides and considered in bioinformatic studies. It should be noted that peptide identification from MS/MS spectra using computational approaches has the potential of producing false positives. Any lysine residue predicted to be modified should be verified experimentally to conclusively demonstrate that this site is indeed ubiquitinated. Bioinformatic analysis. Protein biological processes were analyzed and clus tered by PANTHER 43 after converting the SwissProt accession numbers of identified ubiquitinated proteins into RefSeq protein accession numbers by the Database for Annotation, Visualization and Integrated Discovery (DAVID) 44 online gene ID conversion function. In total, 385 biological processes were found in the database and the category was further grouped into eight classes.
Protein subcellular localization of the ubiquitinated proteins was extracted from the database provides by PENCE Proteome Analyst 45 . Note that some proteins were predicted to have multiple subcellular localizations whereas some proteins have no subcellular information available in the database.
The density map for the diglycinemodified lysines was calculated as fol lows: a subset of protein sequence, 10 amino acids on either side of modified lysines, was extracted from the whole protein sequence. The frequency of each of the 20 individual amino acids at each position from −10 to +10 was calculated for diglycinemodified lysines and this value was normalized to the frequency of the same amino acid at the same position using all lysines in the human SwissProt database to obtain a relative ratio. If the ratio in one position (say −1) for a specific amino acid (say Pro) is >1, there is a commensurately higher likelihood for Pro at the −1 position to be adjacent to a ubiquitinated lysine. The highest relative ratio detected was 2.3 and the range of the color map was set from 0 to 2.5. The density map was prepared by MATLAB. The enriched amino acids were obtained by determining the outliers with a 95% confidence using the Rosner's test 46 .
To access the structural features of ubiquitinated lysine residues for human proteins, we searched crystal structures for all the ubiquitinated proteins in protein database bank (PDB). In total, 89 PDB structures (Supplementary Table 2 ) contained lysines that we found are susceptible to ubiquitination (140 modified lysines and 3970 total lysines). In cases when multiple PDB structures for a ubiquitinated protein were reported, the structure with best quality was used. The secondary structure types for lysines were determined using the program DSSP 47 . H and G were considered to be helix, E and B to be strand, S, T and others for coil. The fraction of each secondary structure type of modified lysines was compared to that of all the lysine residues in 89 PDB structures. The disordered region was predicted by DisEMBL 48 for all identified ubiquitinated proteins and the information for modified lysines and all lysines was extracted. The relative solventaccessible area for the modified and all lysines in 89 crystal structures was calculated using NACCESS 49 with a probe of 1.4 Å, which corresponds to the size of a water molecule.
